NASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis $60.49 +1.24 (+2.09%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$60.50 +0.01 (+0.02%) As of 04/25/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Halozyme Therapeutics Stock (NASDAQ:HALO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Halozyme Therapeutics alerts:Sign Up Key Stats Today's Range$58.49▼$60.9050-Day Range$57.29▼$65.1652-Week Range$37.97▼$66.00Volume992,970 shsAverage Volume1.44 million shsMarket Capitalization$7.47 billionP/E Ratio17.64Dividend YieldN/APrice Target$62.89Consensus RatingModerate Buy Company OverviewHalozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Read More… Halozyme Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreHALO MarketRank™: Halozyme Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 161st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingHalozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageHalozyme Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Halozyme Therapeutics' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth31.50% Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 31.50% in the coming year, from $4.73 to $6.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 17.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 17.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.39.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 20.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Halozyme Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.87% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Halozyme Therapeutics has recently increased by 4.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.12 Percentage of Shares Shorted7.87% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Halozyme Therapeutics has recently increased by 4.34%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News Sentiment0.87 News SentimentHalozyme Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Halozyme Therapeutics this week, compared to 11 articles on an average week.Search InterestOnly 6 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,286,568.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Halozyme Therapeutics' insider trading history. Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Stock News HeadlinesHalozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $32,217.15 in StockApril 2, 2025 | insidertrades.com1HALO : Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings)April 25 at 8:41 AM | benzinga.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.April 27, 2025 | Altimetry (Ad)Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive ReliefApril 24 at 5:38 PM | msn.comHalozyme files patent lawsuit against Merck over injectable KeytrudaApril 24 at 5:38 PM | msn.comHalozyme Therapeutics (HALO) Files Lawsuit Against Merck Over Patent InfringementApril 24 at 10:14 AM | gurufocus.comHalozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda FormulationApril 24 at 8:30 AM | prnewswire.comMijuško ŠibalićApril 23, 2025 | entrepreneur.comSee More Headlines HALO Stock Analysis - Frequently Asked Questions How have HALO shares performed this year? Halozyme Therapeutics' stock was trading at $47.81 on January 1st, 2025. Since then, HALO stock has increased by 26.5% and is now trading at $60.49. View the best growth stocks for 2025 here. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its earnings results on Tuesday, February, 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The biopharmaceutical company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a trailing twelve-month return on equity of 157.78%. Read the conference call transcript. Does Halozyme Therapeutics have any subsidiaries? Halozyme Therapeutics subsidiaries include these companies: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Who are Halozyme Therapeutics' major shareholders? Top institutional investors of Halozyme Therapeutics include Congress Asset Management Co. (1.73%), Boston Trust Walden Corp (0.70%), Rhumbline Advisers (0.34%) and Retirement Systems of Alabama (0.31%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Jeffrey William Henderson, James M Daly and Nicole Labrosse. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and NVIDIA (NVDA). Company Calendar Last Earnings2/18/2025Today4/27/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees390Year Founded1998Price Target and Rating Average Stock Price Target$62.89 High Stock Price Target$75.00 Low Stock Price Target$49.00 Potential Upside/Downside+4.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$3.43 Trailing P/E Ratio17.64 Forward P/E Ratio12.79 P/E Growth0.42Net Income$281.59 million Net Margins43.74% Pretax Margin54.87% Return on Equity157.78% Return on Assets25.34% Debt Debt-to-Equity Ratio4.14 Current Ratio7.80 Quick Ratio9.15 Sales & Book Value Annual Sales$1.02 billion Price / Sales7.36 Cash Flow$4.90 per share Price / Cash Flow12.35 Book Value$2.95 per share Price / Book20.51Miscellaneous Outstanding Shares123,533,000Free Float120,197,000Market Cap$7.47 billion OptionableOptionable Beta1.32 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:HALO) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.